文献速递胸部肿瘤

度伐利尤单抗联合替西木单抗单用或联合低剂量或大分割放疗治疗既往PD(L)-1治疗耐药的转移性非小细胞肺癌:一项开放标签、多中心、随机、2期试验

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2022-01-13

这项开放标签、多中心、随机2期试验在18个美国中心纳入90例既往PD(L)-1治疗进展的转移性NSCLC患者,随机分三组:度伐利尤单抗+替西木单抗单用、联合低剂量放疗或联合大分割放疗。中期分析因无效而终止,三组客观缓解率无差异,放疗未增加缓解。

要点

  • 既往PD(L)-1耐药的转移性NSCLC患者中,度伐利尤单抗+替西木单抗联合放疗未提高客观缓解率。
  • 三组客观缓解率分别为11.5%、7.7%和11.5%,差异无统计学意义。
  • PD-L1联合CTLA-4抑制对部分患者可能是一种治疗选择。

核心结论

  • 放疗未增加PD(L)-1耐药NSCLC患者对PD-L1联合CTLA-4抑制的缓解。
  • PD-L1联合CTLA-4治疗对部分患者可能是一种治疗选择。
  • 未来研究应完善该背景下的预测性生物标志物。

研究设计与样本

  • 开放标签、多中心、随机、2期试验,由美国国家癌症研究所实验治疗临床试验网络在18个美国中心开展。
  • 纳入年龄≥18岁、ECOG体能状态0或1、既往PD(L)-1治疗期间进展的转移性NSCLC患者。
  • 90例患者随机分配(1:1:1)至度伐利尤单抗+替西木单抗单用组、联合低剂量放疗组或联合大分割放疗组,其中78例(每组26例)接受治疗。
  • 主要终点为客观缓解率(最佳局部评估的确认部分或完全缓解),与安全性一起在至少接受一剂研究治疗的患者中分析。

主要发现

  • 中位随访12.4个月(IQR 7.8-15.1),度伐利尤单抗+替西木单抗单用组客观缓解率为3/26(11.5%,90% CI 1.2-21.8)。
  • 低剂量放疗组客观缓解率为2/26(7.7%,0.0-16.3),与单用组比较p=0.64。
  • 大分割放疗组客观缓解率为3/26(11.5%,1.2-21.8),与单用组比较p=0.99。
  • 最常见的3-4级不良事件为呼吸困难(单用组2例[8%]、低剂量放疗组3例[12%]、大分割放疗组3例[12%])和低钠血症(单用组1例[4%] vs 低剂量放疗组2例[8%] vs 大分割放疗组3例[12%])。
  • 治疗相关严重不良事件:单用组1例(4%,斑丘疹),低剂量放疗组5例(19%,腹痛、腹泻、呼吸困难、低钾血症和呼吸衰竭),大分割放疗组4例(15%,肾上腺功能不全、结肠炎、腹泻和低钠血症);低剂量放疗组有1例死亡(呼吸衰竭)可能与研究治疗相关。

关键数值与推荐

  • 度伐利尤单抗1500 mg静脉注射每4周一次,最多13个周期;替西木单抗75 mg静脉注射每4周一次,最多4个周期。
  • 低剂量放疗:0.5 Gy每日两次,在治疗前四个周期的每个周期中重复2天。
  • 大分割放疗:总剂量24 Gy,仅在第一个周期内分三次8 Gy照射。
  • 放疗在初始度伐利尤单抗-替西木单抗给药后1周进行;研究治疗持续至1年或疾病进展。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 该试验因中期分析评估无效而终止。
  • 未来研究应完善该背景下的预测性生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with non-small-cell lung cancer (NSCLC) that is resistant to PD-1 and PD-L1 (PD[L]-1)-targeted therapy have poor outcomes. Studies suggest that radiotherapy could enhance antitumour immunity. Therefore, we investigated the potential benefit of PD-L1 (durvalumab) and CTLA-4 (tremelimumab) inhibition alone or combined with radiotherapy. METHODS: This open-label, multicentre, randomised, phase 2 trial was done by the National Cancer Institute Experimental Therapeutics Clinical Trials Network at 18 US sites. Patients aged 18 years or older with metastatic NSCLC, an Eastern Cooperative Oncology Group performance status of 0 or 1, and progression during previous PD(L)-1 therapy were eligible. They were randomly assigned (1:1:1) in a web-based system by the study statistician using a permuted block scheme (block sizes of three or six) without stratification to receive either durvalumab (1500 mg intravenously every 4 weeks for a maximum of 13 cycles) plus tremelimumab (75 mg intravenously every 4 weeks for a maximum of four cycles) alone or with low-dose (0·5 Gy delivered twice per day, repeated for 2 days during each of the first four cycles of therapy) or hypofractionated radiotherapy (24 Gy total delivered over three 8-Gy fractions during the first cycle only), 1 week after initial durvalumab-tremelimumab administration. Study treatment was continued until 1 year or until progression. The primary endpoint was overall response rate (best locally assessed confirmed response of a partial or complete response) and, along with safety, was analysed in patients who received at least one dose of study therapy. The trial is registered with ClinicalTrials.gov, NCT02888743, and is now complete. FINDINGS: Between Aug 24, 2017, and March 29, 2019, 90 patients were enrolled and randomly assigned, of whom 78 (26 per group) were treated. This trial was stopped due to futility assessed in an interim analysis. At a median follow-up of 12·4 months (IQR 7·8-15·1), there were no differences in overall response rates between the durvalumab-tremelimumab alone group (three [11·5%, 90% CI 1·2-21·8] of 26 patients) and the low-dose radiotherapy group (two [7·7%, 0·0-16·3] of 26 patients; p=0·64) or the hypofractionated radiotherapy group (three [11·5%, 1·2-21·8] of 26 patients; p=0·99). The most common grade 3-4 adverse events were dyspnoea (two [8%] in the durvalumab-tremelimumab alone group; three [12%] in the low-dose radiotherapy group; and three [12%] in the hypofractionated radiotherapy group) and hyponatraemia (one [4%] in the durvalumab-tremelimumab alone group vs two [8%] in the low-dose radiotherapy group vs three [12%] in the hypofractionated radiotherapy group). Treatment-related serious adverse events occurred in one (4%) patient in the durvalumab-tremelimumab alone group (maculopapular rash), five (19%) patients in the low-dose radiotherapy group (abdominal pain, diarrhoea, dyspnoea, hypokalemia, and respiratory failure), and four (15%) patients in the hypofractionated group (adrenal insufficiency, colitis, diarrhoea, and hyponatremia). In the low-dose radiotherapy group, there was one death from respiratory failure potentially related to study therapy. INTERPRETATION: Radiotherapy did not increase responses to combined PD-L1 plus CTLA-4 inhibition in patients with NSCLC resistant to PD(L)-1 therapy. However, PD-L1 plus CTLA-4 therapy could be a treatment option for some patients. Future studies should refine predictive biomarkers in this setting. FUNDING: The US National Institutes of Health and the Dana-Farber Cancer Institute.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Schoenfeld JD, Giobbie-Hurder A, Ranasinghe S, et al. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2022. PMID: 35033226. doi:10.1016/S1470-2045(21)00658-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。